Welcome to the Molecular Pharmacology Group
at the School of Pharmaceutical Sciences
The overall aim of the Molecular Pharmacology Group’s research is the discovery of vascular biology mechanisms and the development of optimized therapeutic strategies for the treatment of complex disease, mainly cancer.
The mainstays of the ongoing research are:
- design of personalized optimization of multidrug combinations,
- identification of novel targets for treatment,
- patient-derived 3D in vitro tumor models,
- cell death mechanisms,
- overcoming acquired resistance of targeted drugs,
- alternative to mammalian screening models,
- nano-systems for co-delivery of multidrug combinations.
We work in a close collaboration with clinicians, engineers, biologists and medical oncologists in order to perform clinically relevant translational research to improve cancer treatment efficacy, reduce side effects and probability of a drug acquired resistance. Our ultimate goal is to develop personalized combination therapies to the dynamically changing tumor response.
- Already online - Special Issue of Angiogenesis: Angiogenesis inhibitors in combinatorial approaches.
Editors: Patrycja Nowak-Sliwinska and Arjan W. Griffioen
- Award for the highly cited article from Journal of Medicinal Chemistry
- Andrea Gasser-Weiss and Patrycja Nowak-Sliwinska awarded with Tony B. Academic Travel Awards SLAS 2017.
- Le Journal (page 5): The protocol that finds the optimal drug combinations: https://epgl.unige.ch/mol-pharmacology/files/journal_web.pdf
- Molecular Pharmacology Group welcomes Marloes Zoetemelk as a PhD student